Post-Marketing Surveillance Data of Adverse Events Following Immunization with Human Rabies Vaccine — China, 2021–2024

What is already known about this topic?: Human rabies vaccine has been in use for many years and has played a vital role in rabies prevention and control in China. What is added by this report?: From 2021 to 2024, the overall reported rate of adverse events following immunization (AEFI) with human rabies vaccine was 18.57 per 100,000 doses, of which 96.29% were common vaccine reactions. Rare vaccine reactions occurred at a rate of 0.49 per 100,000 doses; allergic rash was the most frequently reported rare reaction and usually was non-serious. The rate of rare and serious vaccine reactions was 0.07 per 100,000 doses. What are the implications for public health practice?: Human rabies vaccine, one of the most commonly used non-program vaccines in China, its AEFI rate fell within an acceptable range. Continued AEFI surveillance is essential for evaluating the post-marketing immnization safety of this vaccine.